11 Ways to Better Communicate With Your Colleagues

Slideshow

No matter where you practice medicine, if your duties include patient care then you are going to interact with other oncologists. In some cases you may question the quality of their care. Help your peers to become better physicians by respecting them first, then relaying your concerns to them. Here are some examples of how not to do it, paired with kinder, gentler alternatives.

Artwork by Jon Carter, cartertoons.com

Recent Videos
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
4 experts are featured in this series.
4 experts are featured in this series.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Related Content
Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.

FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC

Russ Conroy
December 18th 2025
Article

Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.

FDA Grants Regular Approval to Rucaparib in Metastatic CRPC

Roman Fabbricatore
December 17th 2025
Article

Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

A clinically meaningful and statistically significant pathologic complete response rate advantage was seen with the enfortumab vedotin combination.

Enfortumab Vedotin Combo Improves Survival in Cisplatin-Eligible MIBC

Roman Fabbricatore
December 17th 2025
Article

A clinically meaningful and statistically significant pathologic complete response rate advantage was seen with the enfortumab vedotin combination.

Fuzuloparib monotherapy and as a combination with apatinib improved PFS as maintenance therapy in patients with ovarian cancer harboring BRCA1/2 mutations.

Fuzuloparib Maintenance Therapies Improve PFS in Newly Diagnosed Ovarian Cancer

Tim Cortese
December 17th 2025
Article

Fuzuloparib monotherapy and as a combination with apatinib improved PFS as maintenance therapy in patients with ovarian cancer harboring BRCA1/2 mutations.